Reducing our carbon footprint while addressing health access in neighbouring, less developed countries.
In 2015 we opened a new pilot vaccine facility at Boronia in Victoria, Australia, to manufacture and test an innovative new production method developed by an Australian-led team. It is hoped this new method will help to reduce overall vaccination costs, which could in turn help more children in developing countries access potentially lifesaving vaccines.
If successful, it will be the first commercial production of a vaccine delivered using ‘blowfill-seal’ technology. At significant volumes, blow-fill-seal (BFS) technology is an efficient, cost-effective way to manufacture high quality, sterile products. In a single process, BFS technology forms the container, fills it with the sterile liquid then seals the container to maintain a high assurance of sterility. No other technology does this with such a small production footprint and without the need for a supply chain of aseptic components.
Putting a life-saving vaccine in BFS containers has the potential to deliver a sterile product in a more compact, robust container and it has a much smaller carbon footprint compared to the current methodology.
During the past four years, GSK has invested more than $100 million in its manufacturing plant in Boronia. It is GSK’s largest site in the Southern Hemisphere and predominantly manufactures respiratory products using BFS. GSK exports approximately 75 per cent of the medicines manufactured in Australia to 58 countries across Europe, the Middle East and Asia.